MYP_088954
Basic Information
Ustekinumab
Anticancer
Standard
226 amino acids
C1083H1678N286O334S9
Standard
Sequence
EVQLVQSGAEVKKPGESLKISCKGSGYSFTTYWLGWVRQMPGKGLDWIGIMSPVDSDIRYSPSFQGQVTMSVDKSITTAYLQWNSLKASDTAMYYCARRRPGQGYFDFWGQGTLVTVSSSSTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH
Physicochemical Analysis
24337.21 Da
9.15
7.05
6.60
0.0312
-0.25
0.58
0.06
51.90
67.61
0.1018
47900.00
48150.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0101473 VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]
Monoclonal antibody
9606
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer
Following administration of a single subcutaneous dose of 45 mg or 90 mg in patients with psoriasis, the median half-life was 19.8 days and 21.2, respectively.